SG11202008971VA - Compositions and methods for treating severe constipation - Google Patents

Compositions and methods for treating severe constipation

Info

Publication number
SG11202008971VA
SG11202008971VA SG11202008971VA SG11202008971VA SG11202008971VA SG 11202008971V A SG11202008971V A SG 11202008971VA SG 11202008971V A SG11202008971V A SG 11202008971VA SG 11202008971V A SG11202008971V A SG 11202008971VA SG 11202008971V A SG11202008971V A SG 11202008971VA
Authority
SG
Singapore
Prior art keywords
compositions
methods
treating severe
severe constipation
constipation
Prior art date
Application number
SG11202008971VA
Other languages
English (en)
Inventor
Brian K Hubbard
Michael H Serrano-Wu
Original Assignee
Anji Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anji Pharmaceuticals Inc filed Critical Anji Pharmaceuticals Inc
Publication of SG11202008971VA publication Critical patent/SG11202008971VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202008971VA 2018-03-16 2019-03-15 Compositions and methods for treating severe constipation SG11202008971VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862644033P 2018-03-16 2018-03-16
PCT/US2019/022499 WO2019178492A1 (en) 2018-03-16 2019-03-15 Compositions and methods for treating severe constipation

Publications (1)

Publication Number Publication Date
SG11202008971VA true SG11202008971VA (en) 2020-10-29

Family

ID=67904819

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008971VA SG11202008971VA (en) 2018-03-16 2019-03-15 Compositions and methods for treating severe constipation

Country Status (24)

Country Link
US (4) US11224590B2 (cg-RX-API-DMAC7.html)
EP (1) EP3765012B1 (cg-RX-API-DMAC7.html)
JP (1) JP7527984B2 (cg-RX-API-DMAC7.html)
KR (1) KR102747096B1 (cg-RX-API-DMAC7.html)
CN (1) CN111936137B (cg-RX-API-DMAC7.html)
AU (1) AU2019234956B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020018790A2 (cg-RX-API-DMAC7.html)
DK (1) DK3765012T3 (cg-RX-API-DMAC7.html)
EA (1) EA202092190A1 (cg-RX-API-DMAC7.html)
ES (1) ES3069001T3 (cg-RX-API-DMAC7.html)
FI (1) FI3765012T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260544T1 (cg-RX-API-DMAC7.html)
IL (1) IL277332B2 (cg-RX-API-DMAC7.html)
LT (1) LT3765012T (cg-RX-API-DMAC7.html)
MX (1) MX2020009604A (cg-RX-API-DMAC7.html)
MY (1) MY205335A (cg-RX-API-DMAC7.html)
PE (1) PE20210158A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551468A1 (cg-RX-API-DMAC7.html)
PL (1) PL3765012T3 (cg-RX-API-DMAC7.html)
PT (1) PT3765012T (cg-RX-API-DMAC7.html)
SG (1) SG11202008971VA (cg-RX-API-DMAC7.html)
SI (1) SI3765012T1 (cg-RX-API-DMAC7.html)
TW (1) TWI704917B (cg-RX-API-DMAC7.html)
WO (1) WO2019178492A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210158A1 (es) 2018-03-16 2021-01-26 Anji Pharmaceuticals Inc Composiciones y metodos para tratar el estrenimiento grave
KR102989262B1 (ko) 2020-10-21 2026-07-08 주식회사 엘지에너지솔루션 전극 탭 고정부를 포함하는 용접장치 및 이를 이용한 전극 탭 용접 방법

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3225997A (en) 1996-05-30 1998-01-05 Trustees Of Columbia University In The City Of New York, The Dna encoding acylcoenzyme a: cholesterol acyltransferase and uses thereof
US20030167483A1 (en) 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
CA2330363C (en) 1998-06-24 2009-10-20 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US6344548B1 (en) 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US20030154504A1 (en) 1998-06-24 2003-08-14 Farese Robert V. Methods and compositions for modulating carbohydrate metabolism
US6100077A (en) 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
WO2002002551A1 (en) 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US6444427B1 (en) 2000-07-11 2002-09-03 The Regents Of The University Of California Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Dgat阻害剤
EP1562956A4 (en) 2002-11-22 2007-10-10 Japan Tobacco Inc HETEROCYCLES CONTAINING FUSED BICYCLIC NITROGEN
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
WO2005013907A2 (en) 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
JP2005206492A (ja) 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
AU2005209115A1 (en) 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorectic compounds
CA2572874A1 (en) 2004-07-02 2006-01-12 Sankyo Company Limited Urea derivative
JP2006045209A (ja) 2004-07-02 2006-02-16 Sankyo Co Ltd ウレア誘導体
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
AU2005295453A1 (en) 2004-10-15 2006-04-27 Bayer Healthcare Llc Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
BRPI0519058A2 (pt) 2004-12-14 2008-12-23 Astrazeneca Ab composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto
MX2007013049A (es) 2005-04-19 2008-01-11 Bayer Pharmaceuticals Corp Preparacion y uso de derivados de aril alquil acido para el tratamiento de la obesidad.
WO2007002740A2 (en) 2005-06-28 2007-01-04 E. I. Du Pont De Nemours And Company Buffer compositions
PT2402319T (pt) * 2006-03-31 2017-12-11 Novartis Ag Inibidores de dgat
GB0611506D0 (en) 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
JO2972B1 (en) * 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009112445A1 (en) * 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
US8324241B2 (en) 2008-04-11 2012-12-04 Bristol-Myers Squibb Company Triazolo compounds useful as DGAT1 inhibitors
SG183529A1 (en) * 2010-03-30 2012-10-30 Novartis Ag Uses of dgat1 inhibitors
JP5841994B2 (ja) * 2010-04-08 2016-01-13 メディシノヴァ, インコーポレイテッド. 過敏性腸症候群の処置方法及びその治療用組成物
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013130370A2 (en) * 2012-03-01 2013-09-06 Merck Sharp & Dohme Corp. Compounds as dgat-1 inhibitors
WO2013169648A1 (en) * 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
BR112015004165A2 (pt) * 2012-08-29 2017-07-04 Salix Pharmaceuticals Inc métodos e composições laxantes para o tratamento de constipação e condições e doenças gastrointestinais relacionadas
CA2932873A1 (en) * 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin aspart
PE20210158A1 (es) 2018-03-16 2021-01-26 Anji Pharmaceuticals Inc Composiciones y metodos para tratar el estrenimiento grave

Also Published As

Publication number Publication date
IL277332A (en) 2020-10-29
US20240293376A1 (en) 2024-09-05
WO2019178492A1 (en) 2019-09-19
US11819495B2 (en) 2023-11-21
SI3765012T1 (sl) 2026-06-30
US20190282549A1 (en) 2019-09-19
LT3765012T (lt) 2026-05-25
TW201944995A (zh) 2019-12-01
BR112020018790A2 (pt) 2020-10-13
IL277332B2 (en) 2025-01-01
FI3765012T3 (fi) 2026-04-17
CA3093970A1 (en) 2019-09-19
PT3765012T (pt) 2026-04-27
EP3765012B1 (en) 2026-03-04
ES3069001T3 (en) 2026-06-03
CN111936137B (zh) 2023-09-08
MY205335A (en) 2024-10-16
PH12020551468A1 (en) 2021-09-01
US20220193044A1 (en) 2022-06-23
EP3765012A4 (en) 2021-12-15
US20260000651A1 (en) 2026-01-01
MX2020009604A (es) 2023-01-25
TWI704917B (zh) 2020-09-21
AU2019234956A1 (en) 2020-10-01
US11224590B2 (en) 2022-01-18
PL3765012T3 (pl) 2026-06-01
JP7527984B2 (ja) 2024-08-05
US12343334B2 (en) 2025-07-01
PE20210158A1 (es) 2021-01-26
DK3765012T3 (da) 2026-04-27
AU2019234956B2 (en) 2025-01-30
EA202092190A1 (ru) 2020-11-19
KR20200136428A (ko) 2020-12-07
JP2021518431A (ja) 2021-08-02
IL277332B1 (en) 2024-09-01
HRP20260544T1 (hr) 2026-07-17
KR102747096B1 (ko) 2024-12-26
EP3765012A1 (en) 2021-01-20
CN111936137A (zh) 2020-11-13

Similar Documents

Publication Publication Date Title
ZA202006627B (en) Methods and compositions for treating cancer
IL286350A (en) Preparations and methods for the treatment of cancer
IL288914A (en) Preparations and methods for the treatment of cancer
GB2578539B (en) Compositions and methods for preventing or treating muscle conditions
IL276808A (en) Preparations and methods for the treatment of cancer
IL274837A (en) Methods and preparations for the treatment of cancer
IL285886A (en) Preparations and methods for the treatment of laminopathy
ZA202104870B (en) Methods and compositions for treating cancer
AU2018297285A1 (en) Compositions and methods for treating or preventing endocrine FGF-linked diseases
SG11202012435UA (en) Compositions and methods for treating cancer
IL271256A (en) Preparations and methods for the treatment of teopathy
IL285796A (en) Methods and preparations for the treatment of cancer
IL325803A (en) Compositions and methods for treating cancer
ZA202101362B (en) Compositions and methods for treating the eye
IL280413A (en) Bismuth-thiol preparations and wound treatment methods
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
PT3810128T (pt) Composições para tratar e/ou prevenir doenças de agregação de proteinas
ZA202101342B (en) Compositions and methods for treating the eye
IL287982A (en) Preparations and methods for the treatment of cancer
SG11202103415WA (en) Compositions and methods for treating and preventing amyotrophic lateral sclerosis
IL277463A (en) Vehicles and methods for treating itch
IL282948B2 (en) Cancer treatment preparations and methods
EP3883588A4 (en) COMPOSITIONS AND METHODS FOR TREATING ENDOMETRIOSIS
IL286153A (en) Methods and preparations for the treatment of cancer
EP3773585A4 (en) Compositions and methods for treating cancer